IGMS: igmbio.com Company Value to Net Income
The prospects for repurposing technologies for the therapy of systemic immune failures will become clear upon the completion of oncology projects, and the capital reserves for research are already priced in. IGM Biosciences, Inc. (IGMS) creates unique IgM structures that bypass analogs due to strong target binding. This price chart with the -0.80 coefficient complements the analysis of a business focused on the commercial release of anti-cancer agents.
%20P%2FE%20Multiple&width=1200&height=400&colorIndex=0&v=mwhdatcg.m7-7dqbc3k&start=20220704&end=20261115&filename=GURU_Markets_-_IGMS_-_IGM-Biosciences-Inc._-_PE-Multiple "IGMS: IGM Bio Business Payback Period 07/04/2022 - 08/24/2025 | 👁️GURU.Markets👁️")
Analytical breakdowns for IGM Bio (IGMS)
- price and consensus price forecast:
- market capitalization information:
- balance sheet net asset value indicators:
- debt and solvency information:
- earnings and market multiples details:
IGMS - Net Profit|Projected Net Profit IGM Biosciences, Inc.|IGMS - Price to Earnings Ratio|Projected Price to Earnings IGM Biosciences|IGMS - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation IGM Biosciences Inc.|IGMS - Operating profit EBITDA|Earnings per share for the last twelve months IGM Biosciences|IGMS - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months igmbio.com|IGMS - Earnings per share growth in current year|Expected net earnings per share growth next year IGM Biosciences, Inc.
- sales volume and revenue indicators:
Comprehensive company analysis:IGM Biosciences IGMS
The development of innovative IgM antibodies to combat cancer determines the capital intensity and payback period for IGM Biosciences, Inc. (IGMS). The price-to-earnings ratio links current R&D expenditures to future cash flow. This coefficient measures the premium investors are willing to pay for control over assets. Sharp fluctuations in this metric signal a revision of market expectations. By analyzing the P/E dynamics of IGM Biosciences, Inc. (IGMS), investors can avoid overpaying when entering a position.
Key competitors
P/E Multiple Argenx|Price to Earnings Ratio BNTX (BioNTech Group)|ABVX (abivax.com) - Company Value to Net Income|P/E Multiple ADMA (admabiologics.com)|Business Payback Period protagonist-inc.com (PTGX)|IMVT - Price to Earnings Ratio|Kiniksa Pharmaceuticals, Ltd. (KNSA) - Price to Earnings Ratio|Grifols Biemat (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotechnologies|Price to Earnings Ratio CLDX|P/E Multiple auriniapharma.com|Price to Earnings Ratio BioCryst Pharmaceuticals Inc (BCRX)|Vera Therapeutics - Price to Earnings Multiple|P/E Multiple DNTH (dianthustx.com)|Pharvaris Pharma (PHVS) - Market Cap to Earnings|AbCellera Biologics - P/E Multiple|tourmalinebio.com - Market Price to Net Income Ratio|Precigen (PGEN) - Price to Earnings Ratio|Pharming Group - Company Value to Net Income|Price to Earnings Ratio Nektar Therapeutics Inc|UPB (Upstream Pharma) - Market Price to Net Income Ratio|P/E Multiple ZBIO|P/E Multiple immunome.com (IMNM)|P/E Multiple GOSS (gossamerbio.com)|Business Payback Period KalVista Pharma (KALV)|SEPN - Price to Earnings Ratio|Business Payback Period Pieris Pharmaceuticals PVLA|SVRA (Savara Inc.) - Price to Earnings Ratio|Market Cap to Net Income RIGL (Rigel Pharmaceuticals)|ANAB (AnaptysBio) - P/E Multiple|ATXS (Astria Therapeutics, Inc.) - Market Price to Net Income Ratio|Price to Earnings Ratio engene.com (ENGN)|RAPT (RAPT Therapeutics, Inc.) - Company Value to Net Income|Aerovate Therapeutics - Price to Earnings Ratio|Company Value to Net Income ACRS|Kyverna Therapeutics, Inc - P/E Multiple|Market Cap to Net Income TLSA|CABA: P/E Multiple|Price to Earnings Ratio Ventyx Bio|Price to Earnings Ratio Theratechnologies, Inc.|Market Cap to Earnings Avalo Therapeutics AVTX|P/E Multiple ELDN|AGEN (Agenus, Inc.) - Company Value to Net Income|Price to Earnings Ratio Climb Bio, Inc. CLYM|Zura Bio Limited (ZURA) - Market Cap to Earnings|ATYR: Price to Earnings Ratio|adagene.com (ADAG) - Price to Earnings Ratio|Ikena Oncology (IMA) - Price to Earnings Ratio|Price to Earnings Ratio Shattuck Labs, Inc.|Price to Earnings Ratio equilliumbio.com|Price to Earnings Ratio connectbiopharm.com (CNTB)|P/E Multiple IMUX|Business Payback Period Atara Bio|Price to Earnings Ratio InflaRx N.V. IFRX|X4 Pharmaceuticals - Price to Earnings Ratio|ACET: Price to Earnings Ratio|Company Value to Net Income CELU (celularity.com)|INMB: P/E Multiple|BRNS: Market Price to Net Income Ratio|KZR (Kezar Life Sciences, Inc.) - P/E Multiple|SAB Biotherapeutics Inc. (SABS) - Business Payback Period|P/E Multiple AKTX|Price to Earnings Ratio ENLV (Enlivex Therapeutics Ltd)|Price to Earnings Ratio Q32 Bio Inc. QTTB|GOVX - Price to Earnings Ratio|EDSA - Price to Earnings Ratio|Market Cap to Earnings iBio|CARM: P/E Multiple|Market Cap to Net Income XTLB (XTL Biopharmaceuticals, Ltd.)|Price to Earnings Ratio boltbio.com|P/E Multiple HCW Biologics|P/E Multiple APVO|AIM - Market Cap to Earnings|P/E Multiple ADTX (Aditxt Inc.)|Business Payback Period GRI Bio, Inc. (GRI)|XRTX - Price to Earnings Ratio|reshapelifesciences.com (HIND) - Price to Earnings Ratio|REVB: P/E Multiple|Indaptus Therapeutics, Inc. - Company Value to Net Income|Price to Earnings Ratio Scinai|Market Cap to Earnings CalciMedica, Inc. CALI|Price to Earnings Ratio Affimed NV (AFMD)|P/E Multiple Allakos Inc (ALLK)|Price to Earnings Ratio hookipapharma.com HOOK|iTeos Therapeutics, Inc. (ITOS) - Market Cap to Earnings|OCEA: Price to Earnings Ratio|Company Value to Net Income TCBP (TC BioPharm (Holdings) PLC)|THRD: P/E Multiple
